 CureVacs CVAC, 8.44 promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities analysts, who upgraded the companys stock to Buy from Neutral on Thursday. They also raised the price target to 18 from 8. 